+86-28-82633987sales@biopurify.com
Batch Structure Search
  • Hot Product:
Home > Product Category > Compound Types > Chalcones

Safflomin A

CAS No.:78281-02-4

Safflomin A
Catalogue No.: BP1235
Formula: C27H32O16
Mol Weight: 612.537
Botanical Source: Carthamus tinctorius L.
Contacts
+86-28-82633397
 
Email me
We are the VIP merchant of PayPal for 8 years, almost no complains, please feel free to buy!


Product name: Safflomin A
Synonym name: Hydroxysafflor yellow A
Catalogue No.: BP1235
Cas No.: 78281-02-4
Formula: C27H32O16
Mol Weight: 612.537
Botanical Source: Main pigment from safflower (Carthamus tinctorius)
Physical Description: Yellow powder
Type of Compound: Chalcones

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle

Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.

The product could be supplied from milligrams to grams, up to kilograms
Inquire for bulk scale.

Descriptions:
Hydroxysafflor yellow A (HSYA), isolated from the dried flower of Carthamus tinctorius L. , which is extensively used in traditional Chinese medicine to treat cirrhosis, can protect against chronic carbon tetrachloride-induced liver fibrosis, might be a promising antifibrotic agent in chronic liver disease.[1]
Hydroxysafflor yellow A can provide protection to H9c2 cardiomyocytes against A/R-induced apoptosis, and this protective effect largely depends on the upregulation of HO-1 expression through the PI3K/Akt/Nrf2 signaling pathway.[2]
Hydroxysafflor yellow A may provide neuroprotection against cerebral ischemia/
reperfusion injury through its suppression of inflammatory responses following focal ischemia reperfusion, and its antioxidant action by inhibiting the opening of mtPTP by a free radical scavenging action in the brain.[3-5]
Hydroxysafflor yellow A could enhance the survival of ECs under hypoxia, which may be correlated with its effect of upregulating the bcl-2/bax ratio and promoting HIF-1 alpha protein accumulation, which increases VEGF, these findings provide evidence for the mechanisms by which HSYA maintains EC survival under hypoxia.[6]
Hydroxysafflor yellow A suppresses inflammatory responses of BV2 microglia after oxygen-glucose deprivation, which is probably associated with the inhibition of the NF-κB signaling pathway and phosphorylation of p38.[7]

References:
[1] Zhang Y, Guo J, Dong H, et al. Eur J Pharmacol, 2011, 660(2–3):438-44.
[2] Liu S X, Zhang Y, Wang Y F, et al. Int J Cardiol, 2012, 160(2):95-101.
[3] Wei X, Liu H, Sun X, et al. Neurosci Lett, 2005, 386(1):58-62.
[4] Tian J, Li G, Liu Z, et al. Pharmacology, 2008, 82(2):121-6.
[5] Ye S Y, Gao W Y. Arch Pharml Res, 2008, 31(8):1010-5.
[6] Ji D B, Zhu M C, Zhu B, et al. J Cardiovasc Pharm, 2008, 52(2):191-202.
[7] Li J. Neurosci Lett, 2013, 535(1):51-6.
[8]Tan S J, Chi J P, He Y Q, et al. Pharm J Chinese Peoples Liberation Army, 2013(05):464-5.